MedTrace Logo

Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection

NCT04264130 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-02-11

No results posted yet for this study

Summary

Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is presently the drug of choice for treating Schistosomiasis (STS), is ineffective on immature stages and there is known parasite resistance. ACTs when combined with PZQ, targeting different stages of the life cycle has shown some effectivity.

Conditions

  • Schistosomiasis Haematobia

Interventions

DRUG

Artesunate-Pyronaridine

Subjects received artesunate-pyronaridine according to their body weight once per day for three days.

DRUG

Artemether-Lumefantrine

subjects received artemether-lumefantrine according to their body weight twice per day for three days.

DRUG

Artefenomel-Ferroquine

Subject received a single dose of artefenomel-ferroquine according to their body weight

Sponsors & Collaborators

  • Centre de Recherche Médicale de Lambaréné

    lead OTHER

Principal Investigators

  • Rella Zoleko Manego · Centre de Recherches Medicales de Lambarene, Lambarene, Gabon

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Gabon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04264130 on ClinicalTrials.gov